Diomed takes EVLT (EndoVenous Laser Treatment) to broader US market:
This article was originally published in Clinica
Diomed Holdings has received US 510(k) clearance to expand the market for its EndoVenous Laser Treatment (EVLT). Since January 2002, the EVLT has been sold for treating venous reflux in the great saphenous vein associated with varicose veins. The new clearance allows the firm's 810nm D15 Plus and D30 Plus laser systems and associated procedure kits to be used for treatment of venous incompetence and for reflux of other superficial veins in the lower extremity. Describing the clearance as a first"s, James Wyli, Diomed's president and CEO, said: "We view this as a further growth opportunity." Lower extremity venous insufficiency affects 20-25% of women and 10-15% of men, said the Andover, Massachusetts firm.